

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 June 2025 (26.06.2025)



(10) International Publication Number
WO 2025/137285 A1

(51) International Patent Classification:
C07D 403/06 (2006.01) A61K 31/5377 (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:
PCT/US2024/061041

(22) International Filing Date:
19 December 2024 (19.12.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/612,552 20 December 2023 (20.12.2023) US

(71) Applicant: **BLACK DIAMOND THERAPEUTICS, INC.** [US/US]; One Main Street, 14th Floor, Cambridge, Massachusetts 02142 (US).

(72) Inventors: **WRONA, Iwona**; 17 Harding Street, Sharon, Massachusetts 02067 (US). **LUCAS, Matthew C.**; 48 Parker Street, Lexington, Massachusetts 02421 (US). **O'CONNOR, Matthew**; 475 Philadelphia Avenue, Massapequa Park, New York 11762 (US). **SMITH, Sherri**; 28 Mitchell Street #3, South Boston, Massachusetts 02127 (US). **SHIN OGAWA, Luisa**; 2320 Commonwealth Avenue, Apt. 2-5, Auburndale, Massachusetts 02466 (US). **JAW-TSAI, Sarah**; c/o Black Diamond Therapeutics, Inc., One Main Street, 14th Floor, Cambridge, Massachusetts 02142 (US).

(74) Agent: **ERLACHER, Heidi** et al.; Cooley LLP, 1299 Pennsylvania Ave. NW, Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,

NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: ALKYNE SUBSTITUTED QUINAZOLINE DERIVATIVES AND USES THEREOF



(57) Abstract: The present disclosure provides compounds (e.g., isolated compounds) of Formula (I) and pharmaceutically acceptable salts thereof. The present disclosure also provides processes for preparing the compounds and uses of the compounds, e.g., in preventing or treating cancer.

WO 2025/137285 A1